Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

Overweight mothers' 'health risk'

Male-specific medicine, still a sensitive subject, has certainly benefited from the heavy marketing and celebrity endorsements which brought erectile dysfunction out of the bedroom and into the doctor's office. Over the last two years, steady growth displayed in the sexual function, sexually transmitted disease, cancer, and urinary treatment segments have boosted the world market for men's health products 7.5% -- from 2003's $16.9 billion to $19.5 billion in 2005.

According to a new Kalorama Information study, Men's Health: The Worldwide Market for Current and Emerging Drug Therapies, market growth will continue at a rate of about 6%, with sales surpassing $26 billion by 2010. A wide range of new product approvals should also contribute to strong growth in the BPH and incontinence segments and gains in prostate and testicular cancer therapeutics.

While the men's sexual dysfunction market has been one of the fastest growing segments within the men's health industry, this highly competitive market is becoming saturated. Kalorama Information estimates that a slow down will ensue over the next few years, bringing the market once projected to reach $7 billion to only $4.3 billion by 2010.

"Newer therapeutics are going to encroach upon the market share of the most popular ED pharmaceuticals, making this sector even more competitive," notes Melissa Elder, the report's author. "Concurrently, other sectors will grow at a more rapid pace as global awareness of men's health issues continues to receive media and medical establishment attention. However, more education is still needed, particularly in Africa and Asia where high risk behaviors among men are prevalent."

Covering drugs used to treat male-specific conditions and conditions of major concern to men, such as herpes and HIV, this 2nd Edition of Men's Health also includes drug research and development pipelines, in-depth company profiles and competitive analysis, global statistics on conditions and diseases affecting men, and market estimates and forecasts for all segments.

Source: http://biz.yahoo.com/prnews